CARDINAL HEALTH INC

CAH

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Driehaus Capital Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 508,093Value: $12.3M

**Signal Note: Driehaus Capital initiates CAH position** Driehaus Capital's new $12.3M position in Cardinal Health (CAH) suggests conviction in the healthcare distributor's valuation or operational recovery, though this represents a pivot away from pure biotech into healthcare infrastructure. The signal may reflect positioning ahead of Cardinal's earnings cycle or confidence in margin expansion from GLP-1 drug distribution tailwinds, given the company's exposure to high-volume specialty pharmaceutical channels.

Deerfield ManagementNEW

More CAH Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

TNDM2 funds NUVL2 funds VEEV2 funds VCYT2 funds PODD2 funds NBIX2 funds BBNX2 funds TMDX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Cardinal Health (CAH) Deerfield Management's $1.8M initiation in CAH signals conviction in healthcare distribution fundamentals, likely driven by margin recovery in pharmaceutical distribution and potential upside from GLP-1 demand normalization post-2024. The position size is modest relative to Deerfield's typical check sizes, suggesting this is a tactical exposure rather than a major thesis bet, possibly hedging broader healthcare services exposure or positioning for Q1 2025 earnings inflection.